The effects of BCL9 KD on the luminal marker CD24 and the basal marker CD44 in DCIS.COM and SUM225 were also assessed by flow cytometry analysis of NT, control and BCL9 KD cells. Here, BCL9 is linked to ductal breast carcinoma in situ.